Acutaas Chemicals Surges 13% to Record High on Strong Q2 Results

Acutaas Raises FY27 Outlook as Quarterly Margins Strengthen

Strong pharmaceutical-intermediate demand and a new South Korean facility are shaping the company’s growth case, while softer specialty chemicals performance remains a counterpoint.

Earnings growth came with a marked margin improvement

Acutaas recorded revenue of ₹436.9 crore in Q2FY27, up 42.7% from a year earlier. EBITDA rose 84.6% to ₹176 crore, while the EBITDA margin expanded to 40.3% from 31.1% in Q2FY26. Gross margin improved by 637 basis points year on year to 62.1%. Profit after tax increased 71.4% to ₹123.1 crore.

The company attributed the quarter’s performance to continued momentum in pharmaceutical intermediates, which offset softer results in specialty chemicals. The mix matters: strong growth in one business can support consolidated earnings, but the weaker segment shows that performance may not be uniform across Acutaas’s markets.

Higher guidance puts execution in focus

Management raised its FY27 revenue growth outlook from 25% to around 30%, citing improved revenue visibility and a robust order pipeline. It also set an EBITDA margin guidance range of 38% to 40%. The revised outlook signals greater confidence in demand and operating performance, but it is a target rather than a guarantee of future results.

The Q2 margin of 40.3% was above the new full-year range. Investors will therefore be watching whether Acutaas can sustain strong profitability as the year progresses, especially with specialty chemicals currently performing more softly. Revenue growth and margin delivery will both be important tests of the raised guidance.

South Korea facility extends the semiconductor opportunity

The company inaugurated its South Korea manufacturing facility ahead of schedule. It is equipped to make high-purity chemicals for photo resists, semiconductor packaging and etching materials, among other applications. The facility gives Acutaas a presence in a specialised part of the semiconductor supply chain, alongside its established pharmaceutical-intermediate business.

This creates a potential avenue for diversification, but the announcement alone does not establish how quickly the facility will contribute to revenue or profits. Its commercial contribution will depend on customer demand and execution; investors should distinguish the strategic opportunity from demonstrated financial performance.

Long-term demand themes are not a substitute for delivery

Acutaas’s annual report points to growth in India’s CDMO and semiconductor markets, supported by pharmaceutical outsourcing and demand for specialised materials. The company also cites the China+1 strategy as an opportunity for Indian manufacturers. These industry trends provide context for its expansion, but market growth does not automatically translate into orders or earnings for an individual company.

The shares rose 13% to ₹3,797 intraday, setting a record, after the results and guidance revision. They had gained 116% in 2026 up to the report, while the Nifty 500 was down 9.4%. That sharp divergence underscores the expectations already embedded in the stock. The focus now shifts to whether operating performance can keep pace with those expectations.

Key Highlights

• Q2FY27 revenue rose 42.7% year on year to ₹436.9 crore.
• EBITDA increased 84.6% to ₹176 crore; the margin reached 40.3%.
• FY27 revenue growth guidance was raised to around 30%, from 25%.
• Management set FY27 EBITDA margin guidance at 38% to 40%.
• The South Korea facility is designed to produce chemicals for semiconductor applications.

Investor Note: The results and upgraded outlook strengthen Acutaas Chemicals’ growth narrative, but the sharp share-price rise also raises the importance of valuation and execution. Investors may want to track guidance delivery, margins and the commercial contribution of the new facility rather than relying on industry growth projections alone.